Saturday, March 25th
  • About Us
  • Copyright
  • Disclaimer
  • Privacy Policy
  • Terms&Conditions
  • Contact Us
    • Advertisement
  • Site Map
Biosimilar News
  • Twitter
  • RSS
  • News/Headlines
  • Events
    • Upcoming Events
    • Past Events
  • Guidelines
  • Policies
  • Research/Analysis
USEFUL TIP: In order not to miss any updates, follow us on Twitter or sign up for our Newsletter..

Follow Us

  • Subscribe by RSS Subscribe by RSS
  • Contact us via E-Mail
  • Follow us on Twitter
  • Follow us on LinkedIn
 

Sign up for our newsletter

All-time Popular Posts

  • A biobetter trastuzumab is on the way A biobetter trastuzumab is on the way
  • EGA president calls on Member States to boost market access for biosimilars in the EU EGA president calls on Member States to boost market access for biosimilars in the EU
  • 3rd Forum on Biosimilars 3rd Forum on Biosimilars
  • Pfizer starts biosimilar rituximab Phase I/II trial Pfizer starts biosimilar rituximab Phase I/II trial
  • Indian Biosimilars Market Indian Biosimilars Market
  • World’s first biosimilar antibody* is approved in Korea World’s first biosimilar antibody* is approved in Korea
  • A biosimilar manufacturer: Celltrion A biosimilar manufacturer: Celltrion
  • 2 patents down, 1 to expire: Herceptin biosimilar coming to EU 2 patents down, 1 to expire: Herceptin biosimilar coming to EU

Tags

adalimumab Amgen Celltrion Clinical Trials Conference EMA Etanercept EU Europe FDA Genentech Guideline Herceptin Hospira Humira India infliximab Interchangeability London Mabthera Monoclonal Antibodies Press Release Remicade Remsima Rituxan rituximab Roche Sandoz South Korea trastuzumab UK USA

Archives

Twitter Updates

Post Tagged with: "Hospira"

June 22, 2016 7:35 AM

Health Canada approves biosimilar infliximab for additional indications: Crohn’s Disease, Fistulising Crohn’s Disease And Ulcerative Colitis

February 10, 2016 11:28 AM

FDA panel backs Celltrion and Pfizer’s Remicade (infliximab) biosimilar

© Copyright 2017 — Biosimilar News. All Rights Reserved Powered by Wordpress